The vision of the FY12 Duchenne Muscular Dystrophy Research Program (DMDRP) is to extend and improve the function, quality of life, and lifespan for all individuals diagnosed with DMD. As such, the DMDRP is seeking to fund research to accelerate the development and clinical testing of new therapeutics and increase our understanding of successes and failures in clinical trials. The DMDRP Therapeutic Idea Award mechanism is designed to promote new ideas that are still in the early stages of development with the potential to yield high-impact data and new avenues of investigation for novel therapeutics for DMD treatment. This award mechanism supports conceptually innovative, high-risk/high-reward research that could ultimately lead to critical discoveries or major advancement in DMD therapeutics. Research projects should include a well-formulated, testable hypothesis based on strong scientific rationale. Research involving human subjects and human anatomical substances is permitted; however, clinical trials are not allowed under this funding opportunity.